208 related articles for article (PubMed ID: 34233557)
1. Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy.
Camus V; Bigenwald C; Ribrag V; Lazarovici J; Jardin F; Sarkozy C
Expert Rev Anticancer Ther; 2021 Sep; 21(9):941-956. PubMed ID: 34233557
[No Abstract] [Full Text] [Related]
2. Pembrolizumab for the treatment of Hodgkin Lymphoma.
Al Hadidi SA; Lee HJ
Expert Opin Biol Ther; 2020 Nov; 20(11):1275-1282. PubMed ID: 33006479
[TBL] [Abstract][Full Text] [Related]
3. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
Godfrey J; Mei M; Chen L; Song JY; Bedell V; Budde E; Armenian S; Puverel S; Nikolaenko L; Chen R; Daniels S; Kennedy N; Peters L; Rosen ST; Forman SJ; Popplewell LL; Kwak LW; Herrera AF
Haematologica; 2024 Feb; 109(2):533-542. PubMed ID: 37470137
[TBL] [Abstract][Full Text] [Related]
4. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
[TBL] [Abstract][Full Text] [Related]
5. The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma.
Tomassetti S; Chen R; Dandapani S
Ther Adv Hematol; 2019; 10():2040620719841591. PubMed ID: 31040936
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of pembrolizumab for classical Hodgkin lymphoma.
Manji F; Laister RC; Kuruvilla J
Expert Rev Hematol; 2022 Apr; 15(4):285-293. PubMed ID: 35389317
[TBL] [Abstract][Full Text] [Related]
7. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
Hradska K; Kascak M; Hajek R; Jelinek T
Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
[No Abstract] [Full Text] [Related]
8. Pembrolizumab for the treatment of diffuse large B-cell lymphoma.
Sheikh S; Kuruvilla J
Expert Opin Biol Ther; 2019 Nov; 19(11):1119-1126. PubMed ID: 31456438
[No Abstract] [Full Text] [Related]
9. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?
Grant C; Dunleavy K; Eberle FC; Pittaluga S; Wilson WH; Jaffe ES
Curr Hematol Malig Rep; 2011 Sep; 6(3):157-63. PubMed ID: 21590365
[TBL] [Abstract][Full Text] [Related]
10. Primary Mediastinal B-Cell Lymphoma in Children and Young Adults.
Forlenza CJ; Chadburn A; Giulino-Roth L
J Natl Compr Canc Netw; 2023 Mar; 21(3):323-330. PubMed ID: 36898366
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Zinzani PL; Ribrag V; Moskowitz CH; Michot JM; Kuruvilla J; Balakumaran A; Zhang Y; Chlosta S; Shipp MA; Armand P
Blood; 2017 Jul; 130(3):267-270. PubMed ID: 28490569
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Armand P; Rodig S; Melnichenko V; Thieblemont C; Bouabdallah K; Tumyan G; Özcan M; Portino S; Fogliatto L; Caballero MD; Walewski J; Gulbas Z; Ribrag V; Christian B; Perini GF; Salles G; Svoboda J; Zain J; Patel S; Chen PH; Ligon AH; Ouyang J; Neuberg D; Redd R; Chatterjee A; Balakumaran A; Orlowski R; Shipp M; Zinzani PL
J Clin Oncol; 2019 Dec; 37(34):3291-3299. PubMed ID: 31609651
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
14. Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma.
Le-Nguyen A; Rys RN; Petrogiannis-Haliotis T; Johnson NA
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1432. PubMed ID: 34047076
[TBL] [Abstract][Full Text] [Related]
15. Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
Gibson SE; Dojcinov S; Dotlic S; Hartmann S; Hsi ED; Klimkowska M; Melle F; Pileri SA; Ramsower CA; Rech K; Rimsza LM; Rodriguez-Pinilla SM; Tousseyn TA; de Jong D; Sabattini E
Virchows Arch; 2023 Dec; 483(6):733-749. PubMed ID: 37530791
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.
de-la-Fuente C; Nuñez F; Cortés-Romera M; Franch-Sarto M; Ribera JM; Sancho JM
Hematol Oncol; 2021 Aug; 39(3):419-422. PubMed ID: 33369766
[TBL] [Abstract][Full Text] [Related]
18. The utility of CD83, fascin and CD23 in the differential diagnosis of primary mediastinal large B-cell lymphoma versus classic Hodgkin lymphoma.
Aladily TN; Mansour A; Alsughayer A; Sughayer M; Medeiros LJ
Ann Diagn Pathol; 2019 Jun; 40():72-76. PubMed ID: 31075666
[TBL] [Abstract][Full Text] [Related]
19. Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling.
Yuan J; Wright G; Rosenwald A; Steidl C; Gascoyne RD; Connors JM; Mottok A; Weisenburger DD; Greiner TC; Fu K; Smith L; Rimsza LM; Jaffe ES; Campo E; Martinez A; Delabie J; Braziel RM; Cook JR; Ott G; Vose JM; Staudt LM; Chan WC;
Am J Surg Pathol; 2015 Oct; 39(10):1322-30. PubMed ID: 26135560
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.
Kim SJ; Yoon DH; Kang HJ; Hong JY; Lee HS; Oh SY; Shin HJ; Kong JH; Yi JH; Sakamoto K; Ko YH; Huh J; Lee SS; Takeuchi K; Shin DY; Suh C; Kim WS
BMC Cancer; 2019 Nov; 19(1):1080. PubMed ID: 31707975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
